Drug intelligence / Profile preview

MVP-201

Development stage: Unknown
Lead developer: Multiverse Pharma
Administration: Intravenous

Overview

MVP-201 is a preclinical-stage blood-brain barrier (BBB) shuttle technology being developed by Multiverse Pharma. The program is designed to overcome the physiological challenges of the BBB, enabling the delivery of therapeutic agents to the central nervous system (CNS). While the specific molecular target and primary disease indications have not been publicly disclosed, the technology is intended to enhance the efficacy of CNS-targeted treatments by improving their brain penetration. As of early 2026, the asset remains in the preclinical phase of development.

Beyond the preview

Go deeper on MVP-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MVP-201.

Explore the full profile